CA2490544A1 - Minimally compliant, volume efficient piston for osmotic drug delivery systems - Google Patents

Minimally compliant, volume efficient piston for osmotic drug delivery systems Download PDF

Info

Publication number
CA2490544A1
CA2490544A1 CA002490544A CA2490544A CA2490544A1 CA 2490544 A1 CA2490544 A1 CA 2490544A1 CA 002490544 A CA002490544 A CA 002490544A CA 2490544 A CA2490544 A CA 2490544A CA 2490544 A1 CA2490544 A1 CA 2490544A1
Authority
CA
Canada
Prior art keywords
piston
osmotic
agent
interior
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002490544A
Other languages
French (fr)
Other versions
CA2490544C (en
Inventor
Scott D. Lautenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2490544A1 publication Critical patent/CA2490544A1/en
Application granted granted Critical
Publication of CA2490544C publication Critical patent/CA2490544C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M2005/14513—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons with secondary fluid driving or regulating the infusion

Abstract

An osmotic pump having a minimally compliant, volume efficient piston positioned within a capsule. The capsule has an interior surface, a benefici al agent, and an osmotic agent. The piston is movable with respect to an interi or surface of the capsule, and defines a movable seal with the interior surface of the capsule. The movable seal separates the osmotic agent from the beneficial agent. The piston has a length to total diameter ratio of about 1.1:1 and a core diameter to total diameter ratio of about 0.9:1. The piston enables greater beneficial agent and/or osmotic agent payload without increasing the size of the capsule. The osmotic agent imbibes liquid from a surrounding environment through a semipermeable body to cause the piston to move and in turn cause delivery of the beneficial agent from the capsule.</S DOAB>

Claims (16)

1. An osmotic delivery system comprising:
a capsule, said capsule having an interior for holding a beneficial agent, said interior having an interior surface;
an osmotic agent located in said interior;
a semipermeable body in liquid communication with said capsule for permitting liquid to permeate through said semipermeable body to said osmotic agent; and a piston having a length to total diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1 located within said interior of said capsule, being movable with respect to said interior surface of said capsule, defining a movable seal with said interior surface of said capsule that separates said osmotic agent from the beneficial agent;
said osmotic agent located between said piston and said semipermeable body, said osmotic agent for imbibing fluid from a surrounding environment through said semipermeable body to cause said piston to move and in turn cause delivery of the beneficial agent from said capsule.
2. The osmotic delivery system according to Claim 1, wherein said piston includes one or a plurality of ribs for effecting said seal with said interior surface.
3. The osmotic delivery system according to Claim 1, wherein said capsule includes a cylindrical tube.
4. The osmotic delivery system according to Claim 3, wherein said cylindrical tube includes an opening and said semipermeable body includes a semipermeable plug, said semipermeable plug located within said opening.
5. The osmotic delivery system according to Claim 1, wherein said osmotic agent includes a tablet.
6. An osmotic delivery system comprising:

a piston having a length to overall diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1;
an osmotic agent; and an enclosure having an interior holding said piston and said osmotic agent, said piston being movable with respect to said enclosure, and said enclosure having a semipermeable body in liquid communication with said osmotic agent for permitting liquid to permeate through said semipermeable body to said osmotic agent, said osmotic agent for imbibing fluid from a surrounding environment and causing said piston to move.
7. The osmotic delivery system according to Claim 6, wherein said interior of said enclosure includes an interior surface, said piston abutting against said interior surface.
8. The osmotic delivery system according to Claim 6, wherein said semipermeable body is located within said interior of said enclosure.
9. The osmotic delivery system according to Claim 6, wherein said enclosure is fluid impermeable.
10. The osmotic delivery system according to Claim 6, wherein said osmotic agent is located between said semipermeable body and said piston.
11. The osmotic delivery system according to Claim 6, further comprising a beneficial agent located in said interior of said enclosure, said beneficial agent being delivered from said enclosure when said piston moves.
12. The osmotic delivery system according to Claim 6, wherein said piston is fluid impermeable.
13. The osmotic delivery system according to Claim 6, wherein said piston includes at least one rib for effecting a movable seal with said enclosure.
14. The osmotic delivery system according to Claim 6, further comprising a beneficial agent located in said interior of said enclosure, said piston defining a movable seal that separates said osmotic agent from said beneficial agent.
15. An osmotic delivery system comprising:
a capsule having a tubular interior, said tubular interior having an interior surface;
a semipermeable body located at least partially within said tubular interior;
an osmotic agent located between said semipermeable body and said piston;
a beneficial agent located within said tubular interior; and a piston located within said tubular interior, said piston having a length to overall diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1, said piston separating said beneficial agent from said osmotic agent, and being movable with respect to said interior surface of said tubular interior and with respect to said semipermeable body.
16. The osmotic delivery system according to Claim 15, wherein the piston includes at least one rib.
CA2490544A 2002-06-26 2003-06-25 Minimally compliant, volume efficient piston for osmotic drug delivery systems Expired - Fee Related CA2490544C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39200402P 2002-06-26 2002-06-26
US60/392,004 2002-06-26
PCT/US2003/020130 WO2004002565A1 (en) 2002-06-26 2003-06-25 Minimally compliant, volume efficient piston for osmotic drug delivery systems

Publications (2)

Publication Number Publication Date
CA2490544A1 true CA2490544A1 (en) 2004-01-08
CA2490544C CA2490544C (en) 2011-04-19

Family

ID=30000792

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2490544A Expired - Fee Related CA2490544C (en) 2002-06-26 2003-06-25 Minimally compliant, volume efficient piston for osmotic drug delivery systems

Country Status (20)

Country Link
US (3) US6939556B2 (en)
EP (1) EP1551493B1 (en)
JP (1) JP4485945B2 (en)
KR (1) KR101046903B1 (en)
CN (1) CN100453130C (en)
AT (1) ATE376854T1 (en)
AU (1) AU2003256308B2 (en)
BR (1) BR0312429A (en)
CA (1) CA2490544C (en)
DE (1) DE60317225T2 (en)
EC (1) ECSP055578A (en)
ES (1) ES2295642T3 (en)
HK (1) HK1080402A1 (en)
IL (1) IL165975A (en)
MX (1) MXPA05000224A (en)
NO (1) NO20050368L (en)
NZ (1) NZ537628A (en)
TW (1) TW200531709A (en)
WO (1) WO2004002565A1 (en)
ZA (1) ZA200500744B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
KR20050088196A (en) * 2002-12-19 2005-09-02 알자 코포레이션 Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CL2004000696A1 (en) * 2003-03-31 2005-05-20 Alza Corp OSMOTIC PUMP, IS FORMED BY A CYLINDER COVER WITH A CAMERA THAT RECEIVES THE OSMOTIC AGENT, AN OPEN END THAT RECEIVES A SEMIPERMEABLE PLUG AND A VENTILATION HOLE IN THE SIDE WALL LOCATED NEXT TO THE OPEN END, FOR DISI
JP2006521898A (en) * 2003-03-31 2006-09-28 アルザ・コーポレーション Osmotic delivery system and method for reducing start-up time of an osmotic delivery system
US20050101943A1 (en) * 2003-11-06 2005-05-12 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
WO2006058059A2 (en) 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
JP2008528698A (en) * 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド Implantable interferon-containing devices
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
BRPI0607017B8 (en) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc pharmaceutical composition comprising memantine and donezepil, and their use for the treatment of snc-related conditions
US20070208041A1 (en) * 2005-10-13 2007-09-06 Stamler Jonathan S Compositions for the treatment and prevention of heart disease and methods of using same
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
CN101715340A (en) 2007-04-23 2010-05-26 精达制药公司 The mixed suspension preparation of insulinotropic peptide and application thereof
US8105261B2 (en) * 2007-07-02 2012-01-31 Cardiac Pacemakers, Inc. Osmotic devices and methods for diuretic therapy
US8394644B2 (en) * 2007-11-08 2013-03-12 Honeywell International Inc. Microfluidic osmotic pump
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CA2738715C (en) * 2008-10-15 2013-07-16 Intarcia Therapeutics, Inc. Highly concentrated drug particles, formulations, suspensions and uses thereof
EA023156B1 (en) * 2009-06-26 2016-04-29 ТАРИС Биомедикал ЛЛК Drug delivery device
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
JP2013506689A (en) 2009-09-30 2013-02-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cofactors and how to use them for individuals
WO2011069010A2 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2014059444A2 (en) * 2012-10-12 2014-04-17 Eli Lilly And Company Chemical engines and methods for their use, especially in the injection of highly viscous fluids
WO2014078459A1 (en) 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
AU2014207707B2 (en) 2013-01-15 2018-11-01 Nusirt Sciences, Inc. Treating pulmonary conditions
EP2964310A1 (en) * 2013-03-05 2016-01-13 TARIS Biomedical LLC Drug delivery devices and methods for controlled drug release through device orifice
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (en) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 Implant placement and removal systems
RU2020141860A (en) 2015-11-05 2021-04-01 Дзе Дженерал Хоспитал Корпорейшн INTRATEKAL DELIVERY OF NUCLEIC ACID SEQUENCES CODING ABCD1 FOR ADRENOMYELONEUROPATHY TREATMENT
BR112018012870A2 (en) 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc methods and compositions for the treatment of crisis-related disorders
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
CA3040906A1 (en) 2016-10-20 2018-04-26 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JP6841937B2 (en) 2017-02-17 2021-03-10 イーライ リリー アンド カンパニー Processes and devices for the delivery of fluids by chemical reactions
CN110545838A (en) 2017-03-08 2019-12-06 因塔西亚制药公司 apparatus and method for administering nausea-causing compounds from a drug delivery device
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
EP3840735A4 (en) * 2018-08-23 2022-06-15 Baywind Bioventures Capsule device for delivery of active agent to gastrointestinal tract
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753651A (en) 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4558888A (en) * 1983-09-19 1985-12-17 Minnesota Mining And Manufacturing Company Strip of binding tape
US4874388A (en) 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5728088A (en) 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5234424A (en) 1988-12-28 1993-08-10 Alza Corporation Osmotically driven syringe
US4969884A (en) 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5861166A (en) 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
CN2085662U (en) * 1991-03-29 1991-10-02 毕勇 Productive device for "osmotic pump" of medicines
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
DE69229881T2 (en) 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical DELAYED RELEASE TABLET
CA2115648C (en) 1991-10-10 2002-04-09 Eun Soo Lee Osmotic drug delivery devices with hydrophobic wall materials
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5540665A (en) 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5690952A (en) 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
ATE284202T1 (en) 1996-02-02 2004-12-15 Alza Corp IMPLANTABLE DELAYED RELEASE SYSTEM
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
CA2316976C (en) 1997-12-29 2009-02-17 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry

Also Published As

Publication number Publication date
AU2003256308B2 (en) 2008-07-03
DE60317225T2 (en) 2008-05-29
WO2004002565A1 (en) 2004-01-08
ATE376854T1 (en) 2007-11-15
IL165975A0 (en) 2006-01-15
CN100453130C (en) 2009-01-21
AU2003256308A1 (en) 2004-01-19
EP1551493A1 (en) 2005-07-13
DE60317225D1 (en) 2007-12-13
ECSP055578A (en) 2005-04-18
US20070088337A1 (en) 2007-04-19
US20040019345A1 (en) 2004-01-29
JP4485945B2 (en) 2010-06-23
EP1551493B1 (en) 2007-10-31
HK1080402A1 (en) 2006-04-28
TW200531709A (en) 2005-10-01
KR20050026416A (en) 2005-03-15
KR101046903B1 (en) 2011-07-06
CN1671439A (en) 2005-09-21
MXPA05000224A (en) 2005-06-03
US20060111693A1 (en) 2006-05-25
ZA200500744B (en) 2006-03-29
BR0312429A (en) 2005-04-19
CA2490544C (en) 2011-04-19
JP2005530588A (en) 2005-10-13
NO20050368L (en) 2005-01-24
US6939556B2 (en) 2005-09-06
NZ537628A (en) 2005-12-23
IL165975A (en) 2009-07-20
US7112335B2 (en) 2006-09-26
ES2295642T3 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
CA2490544A1 (en) Minimally compliant, volume efficient piston for osmotic drug delivery systems
JP2005530588A5 (en)
WO2000040218A3 (en) Osmotic delivery system having space efficient piston
US4203442A (en) Device for delivering drug to a fluid environment
WO2001045675A3 (en) Valve for osmotic devices
ES2243738T3 (en) OSMOTIC IMPLANT WITH MEMBRANE AND MEMBRANE RETENTION ORGAN.
CO4970812A1 (en) OSMOTIC SUPPLY SYSTEMS, ASSEMBLY OF THE BODY OF THE OSMOTIC SUPPLY SYSTEM AND SYSTEM TO CONTROL THE SUPPLY RATE OF BENEFICIAL AGENTS OF THE OSMOTIC SUPPLY SYSTEM.
ES2671180T3 (en) Plunger for medicinal hollow body and medicinal hollow body
KR20060017749A (en) Osmotic pump with means for dissipating internal pressure
WO2005039668A3 (en) Implantable drug delivery device for sustained release of therapeutic agent
DE69425828T2 (en) OSMOTIC DEVICE WITH VAPOR-PERMEABLE COATING
CA2651855A1 (en) Two-piece, internal-channel osmotic delivery system flow modulator
NO307245B1 (en) Disposable dispenser intended for medication
WO2007056131B1 (en) Continuously sealing one way valve assembly and fluid delivery system formulations for use therein
JP2005255253A (en) Capsule for storing, mixing and dispensing material
WO2001052919A3 (en) Needleless syringe
CA2489325A1 (en) Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
EP2773414A1 (en) Osmotically active vaginal delivery system
CA2492836A1 (en) Administration device comprising an osmotic drive
CA2468788A1 (en) Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
CN107708608B (en) Predetermined close liquid-based substance saves tubule and injection device and method using tubule
EP1904746A2 (en) Fluid delivery device
BR9811670A (en) Improvements related to containers for medicinal products.
DK0934754T3 (en) Needleless medical device for administration of therapeutic agent
WO1995013760A1 (en) Gas driven controlled release device

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210625